French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, helped by ...

The blockbuster Sanofi and Regeneron Pharmaceuticals drug Dupixent, already commercialized in several skin and lung disorders, has expanded its FDA-approval to chronic obstructive pulmonary ...

The French drugmaker on Monday announced progress on a deal to sell 50% of its over-the-counter division to Clayton Dubilier ...

By Ludwig Burger (Reuters) -French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in ...

MC: There is no old or new model, but there is old school thinking and open school thinking. We are clearly conscious of this within Sanofi and we truly believe that we will overcome the future ...

Sanofi said this morning that its pipeline includes ... build-up to an R&D presentation to investors that will be held in New York later today, and also after the France-headquartered group ...

Regeneron REGN-0.84%decrease; red down pointing triangle Pharmaceuticals and Sanofi SAN 0.18%increase; green up pointing triangle have won U.S. Food and Drug Administration expanded approval of ...

French healthcare company Sanofi has decided to halt work on its once praised breast cancer medication amcenestrant after a second failed clinical trial. A possible new coronavirus vaccine ...

Sanofi is deepening its commitment to targeted radiation treatments for cancer with a €300 million equity investment in a new entity pursuing next-generation radioligand therapies. The new ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

French pharmaceutical company Sanofi had asked suitors to revise their proposals for the Opella business, Bloomberg News reported earlier this week. The new bids may exclude parts of the Gold Bond ...

This newsletter was penned in the company of some mastodon fossils in New York. They say good morning, too. Today, we see an escalating battle between Eli Lilly and compounding pharmacies putting ...